Drug interaction studies between paclitaxel (Taxol) and OC144-093 — A new modulator of MDR in cancer chemotherapy (original) (raw)

• Newman MJ, Rodarte JC, Benbatoul KD, Romano SJ, Uyeda RT, Moran EJ, Dixon R, Guns ES and Mayer LD (2000) Discovery and Characterization of OC144-093, a novel inhibitor of Pgp mediated MDR. Cancer Research. 60(11):2964–72.
  PubMed CAS Google Scholar
• Bellamy William T (1996) P-glycoproteins and multidrug resistance. Annu. Rev. Pharmacol. Toxicol. 36:161–183.
  Article Google Scholar
• Wacher VJ, Wu C-Y and Benet LZ (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinogenesis. 13:129–134.
  Article CAS Google Scholar
• Guns ES, Bullock PL, Reimer MLJ, Dixon R and Mayer LD (2001) Assessment of the involvement of CYP3A in the in vitro metabolism of a new modulator of MDR in cancer chemotherapy, OC144-093, by human liver microsomes. Eur J Drug Metab Pharm 26(4):273–282.
  CAS Google Scholar
• Sonnichsen DS, Liu Q, Schuetz EG, Schuetz JD, Pappo A and Relling MV (1995). Variability in human cytochrome P450 paclitaxel metabolism. J Pharmacol Exp Ther. 275(2):566–75.
  PubMed CAS Google Scholar
• Endicott JA and Ling V (1989) The Biochemistry of P-Glycoprotein mediated multidrug resistance. Annu. Rev. Biochem. 58:137–71.
  Article PubMed CAS Google Scholar
• Cordon-Cardo C and O’Brien JP (1991) The multi-drug resistance phenotype in human cancer, in Important Advances in Oncology, (De Vita VT, Hellman S, Rosenberg SA) pp 19–38, Lippincott, Philadelphia.
  Google Scholar
• Cordon CC, O’Brien JP, Casals D, Rittman-Grauer L., Biedler JL, Melamed MR and Bertino JR (1989) Multi-drug resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. USA. 86:695–698.
  Article Google Scholar
• Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC (1989) Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J Histochem. 37:159–64.
  CAS Google Scholar
• Grogan TM, Spier CM, Salmon SE, Matzner M and Rybski J (1993) P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 81:490–95.
  PubMed CAS Google Scholar
• Drori S., Eytan, GD and Assaraf YG (1995) Potentiation of anticancer drug cytotoxicity by multidrug-resistance chemosensitizers involves alterations in membrane fluidity leading to increased membrane potential. Eur. J. Biochem. 228:1020–1029.
  Article PubMed CAS Google Scholar
• Pereira E, Teodori E, Dei D, Gualtieri F and Garnier-Suillerot A (1995) Reversal of multidrug resistance by verapamil analogues. Biochem. Pharmacol. 50(4):451–457.
  Article PubMed CAS Google Scholar
• Radel S, Bankusli I, Mayhew E and Rustum YM (1988) The effects of verapamil and a tiapamil analogue, DMDP, on adriamycin-induced cytotoxicity in P388 adriamycin-resistant and-sensitive leukemia in vitro and in vivo. Cancer Chemother. Pharmacol. 21:25–30.
  Article PubMed CAS Google Scholar
• Sikic BI, Fisher GA and Lum BL (1997) Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother. Pharmacol. 40(Suppl):S13-S19.
  Article PubMed CAS Google Scholar
• Keller RP, Altermatt HJ, Nooter K, Poschmann G, Laissue JA, Bollinger P and Hiestand PC (1992) SDZ PSC833, a non-immunosuppressive cyclosporin: its potency in overcoming P-glycoprotein mediated multidrug resistance of murine leukemia. Int J. Cancer 50:593–597.
  Article PubMed CAS Google Scholar
• Erlichman C, Moore M, Thiessen JJ, Kerr IG, Walker S, Goodman P, Bjarnason G, Deangelis C. and Bunting P (1993) Phase I pharmacokinetic study of Cyclosporin A combined with Doxorubicin. Cancer Research. 53:4837–4842.
  PubMed CAS Google Scholar
• Kerr J, Graham J, Cummings J, Morrison JG, Thompson GG, Brodie MJ and Kaye SB (1986) The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemother. Pharmacol. 18:239–242.
  Article PubMed CAS Google Scholar
• Zhou-Pan XR, Seree E, Zhou XJ, Placidi M, Maurel P, Barra Y and Rahmani R (1993) Involvement of Human Liver Cytochrome P450 3A in Vinblastine Metabolism: Drug Interactions. Cancer Research 53: 5121–5126.
  PubMed CAS Google Scholar
• Rushing DA, Raber SR, Rodvold KA, Piscitelli SC, Plank GS, Tewksbury DA (1994) The effects of Cyclosporine on the Pharmacokinetics of Doxorubicin in Patients with Small Cell Lung Cancer. Cancer 74:834–841.
  Article PubMed CAS Google Scholar
• Henricsson S, Lindholm A and Aravoglou M (1990) Cyclosporin metabolism in human liver microsomes and its inhibition by other drugs. Pharmacology and Toxicology 66:49–52.
  PubMed CAS Google Scholar
• Marre F, Sanderink G-J, De Sousa G, Gaillard C, Martinet M and Rahmani R (1996) Hepatic Biotransformations of Docetaxel (Taxotere”) in vitro: Involvement of the CYP3A Subfamily in Humans. Cancer Research 56:1296–1302.
  PubMed CAS Google Scholar
• Kivisto KT, Kroemer HK and Eichelbaum M (1995) The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br. J. Clin. Pharmacol. 40:523–530.
  PubMed CAS Google Scholar
• Van Asperen J, Van Tellingen O, Sparreboom A, Schinkel AH, Borst P, Nooijen WJ and Beijnen JH (1997) Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZPSC 833. Br J Cancer. 76(9):1181–3.
  PubMed Google Scholar
• Purba HS, Back DJ and Orme LLE (1987) Tolbutamide 4-hydroxylase activity of human liver microsomes: Effect of inhibitors. Br. J. Clin. Pharmacol. 24:230–234.
  PubMed CAS Google Scholar
• Desai PB, Duan JZ, Zhu YW and Kouzi S (1998) Human liver microsomal metabolism of paclitaxel and drug interactions. Eur J Drug Metab Pharmacokinet. 23(3):417–24.
  PubMed CAS Google Scholar
• Maurice M, Pitchard L, Daujat M, Fabre I, Joyeux H, Domergue J and Maurel P (1992) Effects of imidazole derivatives on cytochrome P-450 from human hepatocytes in primary culture. Fed. Am. Soc. Exp. Biol. 6:752–758.
  PubMed CAS Google Scholar
• Chang T, Benet LZ, and Hebert MF (1996) The effect of water-soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers. Clin. Pharmacol. Ther. 59:297–303.
  Article PubMed CAS Google Scholar
• Fischer V, Rodriguez-Gascon A, Heitz F, Tynes R, Hauck C, Cohen D, Vickers AE (1998) The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite. Drug Metab. Dispos. 26:802–11.
  PubMed CAS Google Scholar